Inflammation Research

, 60:1021 | Cite as

Fibrinolysis is down-regulated in mouse collagen-induced arthritis, but its normalization does not alleviate the course of disease

  • Jakub KwiecińskiEmail author
  • Elisabet Josefsson
  • Tao Jin
Original Research Paper



Down-regulation of fibrinolysis and increased fibrin deposition in joints are hallmarks of rheumatoid arthritis (RA), and are believed to be involved in disease progression. The mouse model of collagen-induced arthritis (CIA) closely resembles RA and has been used to explore mechanism and treatments of RA, but neither the fibrinolytic system nor pro-fibrinolytic therapies were investigated in CIA.

Materials and methods

Plasmin activity, levels of plasminogen activator inhibitor (PAI-1), D-dimer, and IL-6 were measured in plasma of CIA mice. Fibrin deposition and PAI-1 levels were also measured in inflamed joints. Mice were treated with plasminogen activators uPA (urokinase-type plasminogen activator) or tPA (tissue-type plasminogen activator). Effects of treatment on disease severity and fibrinolytic system were assessed.


CIA caused decrease in plasmin activity, accompanied by increase in PAI-1 levels, in both blood and inflamed joints. This resulted in massive fibrin deposition in synovium. PAI-1 levels correlated negatively with plasmin activity and positively with IL-6. Treatments with uPA and tPA improved plasmin activity and removed fibrin deposits in inflamed joints. However, disease severity remained unchanged.


Fibrinolytic changes in CIA parallel changes in RA, making CIA a suitable model to study fibrinolysis in RA. Normalization of plasmin activity in CIA after treatment with plasminogen activators had no effect on disease severity.


Rheumatoid arthritis Collagen-induced arthritis Fibrinolysis Plasmin tPA uPA 



Authors are grateful to Malin Erlandsson and Ing-Marie Jonsson for their excellent technical assistance and to Maria Bokarewa for critical reading of the manuscript. This work was supported by Göteborg Medical Society, King Gustaf V:s Foundation, Åke Wiberg’s Foundation, Nanna Svartz’ Foundation, Rune and Ulla Amlöv’s Foundation, Swedish Rheumatism Association, Göteborg Rheumatism Association, The family Thölens and Kristlers Foundation, Tore Nilsson’s Foundation, and the University of Göteborg.


  1. 1.
    Busso N, Hamilton JA. Extravascular coagulation and the plasminogen activator/plasmin system in rheumatoid arthritis. Arthritis Rheum. 2002;46(9):2268–79. doi: 10.1002/art.10498.PubMedCrossRefGoogle Scholar
  2. 2.
    Hamilton JA. Plasminogen activator/plasmin system in arthritis and inflammation: friend or foe? Arthritis Rheum. 2008;58(3):645–8. doi: 10.1002/art.23269.PubMedCrossRefGoogle Scholar
  3. 3.
    Brommer EJ, Dooijewaard G, Dijkmans BA, Breedveld FC. Plasminogen activators in synovial fluid and plasma from patients with arthritis. Ann Rheum Dis. 1992;51(8):965–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Busso N, Peclat V, So A, Sappino AP. Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints. Ann Rheum Dis. 1997;56(9):550–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Ronday HK, Smits HH, Van Muijen GN, Pruszczynski MS, Dolhain RJ, Van Langelaan EJ, et al. Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Br J Rheumatol. 1996;35(5):416–23.PubMedCrossRefGoogle Scholar
  6. 6.
    Wallberg-Jonsson S, Rantapaa-Dahlqvist S, Nordmark L, Ranby M. Mobilization of fibrinolytic enzymes in synovial fluid and plasma of rheumatoid arthritis and spondyloarthropathy and their relation to radiological destruction. J Rheumatol. 1996;23(10):1704–9.PubMedGoogle Scholar
  7. 7.
    Belcher C, Fawthrop F, Bunning R, Doherty M. Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees. Ann Rheum Dis. 1996;55(4):230–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Brommer EJ, Dooijewaard G, Dijkmans BA, Breedveld FC. Depression of tissue-type plasminogen activator and enhancement of urokinase-type plasminogen activator as an expression of local inflammation. Thromb Haemost. 1992;68(2):180–4.PubMedGoogle Scholar
  9. 9.
    Jin T, Tarkowski A, Carmeliet P, Bokarewa M. Urokinase, a constitutive component of the inflamed synovial fluid, induces arthritis. Arthritis Res Ther. 2003;5(1):R9–17.PubMedCrossRefGoogle Scholar
  10. 10.
    Kummer JA, Abbink JJ, de Boer JP, Roem D, Nieuwenhuys EJ, Kamp AM, et al. Analysis of intraarticular fibrinolytic pathways in patients with inflammatory and noninflammatory joint diseases. Arthritis Rheum. 1992;35(8):884–93.PubMedCrossRefGoogle Scholar
  11. 11.
    Saxne T, Lecander I, Geborek P. Plasminogen activators and plasminogen activator inhibitors in synovial fluid. Difference between inflammatory joint disorders and osteoarthritis. J Rheumatol. 1993;20(1):91–6.PubMedGoogle Scholar
  12. 12.
    Weinberg JB, Pippen AM, Greenberg CS. Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum. 1991;34(8):996–1005.PubMedCrossRefGoogle Scholar
  13. 13.
    Carmassi F, De Negri F, Morale M, Puccetti R, Chung SI. Elastase- and plasmin-mediated fibrinolysis in rheumatoid arthritis. Int J Tissue React. 1994;16(2):89–93.PubMedGoogle Scholar
  14. 14.
    Kopeikina LT, Kamper EF, Koutsoukos V, Bassiakos Y, Stavridis I. Imbalance of tissue-type plasminogen activator (t-PA) and its specific inhibitor (PAI-1) in patients with rheumatoid arthritis associated with disease activity. Clin Rheumatol. 1997;16(3):254–60.PubMedCrossRefGoogle Scholar
  15. 15.
    Barnhart MI, Riddle JM, Bluhm GB, Quintana C. Fibrin promotion and lysis in arthritic joints. Ann Rheum Dis. 1967;26(3):206–18.PubMedCrossRefGoogle Scholar
  16. 16.
    Clemmensen I, Holund B, Andersen RB. Fibrin and fibronectin in rheumatoid synovial membrane and rheumatoid synovial fluid. Arthritis Rheum. 1983;26(4):479–85.PubMedCrossRefGoogle Scholar
  17. 17.
    Zacharski LR, Brown FE, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM, et al. Pathways of coagulation activation in situ in rheumatoid synovial tissue. Clin Immunol Immunopathol. 1992;63(2):155–62.PubMedCrossRefGoogle Scholar
  18. 18.
    Sanchez-Pernaute O, Largo R, Calvo E, Alvarez-Soria MA, Egido J, Herrero-Beaumont G. A fibrin based model for rheumatoid synovitis. Ann Rheum Dis. 2003;62(12):1135–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C, Senshu T, et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol. 2001;166(6):4177–84.PubMedGoogle Scholar
  20. 20.
    Busso N, Peclat V, Van Ness K, Kolodziesczyk E, Degen J, Bugge T, et al. Exacerbation of antigen-induced arthritis in urokinase-deficient mice. J Clin Invest. 1998;102(1):41–50. doi: 10.1172/JCI2312.PubMedCrossRefGoogle Scholar
  21. 21.
    Flick MJ, LaJeunesse CM, Talmage KE, Witte DP, Palumbo JS, Pinkerton MD, et al. Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alphaMbeta2 binding motif. J Clin Invest. 2007;117(11):3224–35. doi: 10.1172/JCI30134.PubMedCrossRefGoogle Scholar
  22. 22.
    Brand DD, Kang AH, Rosloniec EF. Immunopathogenesis of collagen arthritis. Springer Semin Immunopathol. 2003;25(1):3–18. doi: 10.1007/s00281-003-0127-1.PubMedCrossRefGoogle Scholar
  23. 23.
    Cho YG, Cho ML, Min SY, Kim HY. Type II collagen autoimmunity in a mouse model of human rheumatoid arthritis. Autoimmun Rev. 2007;7(1):65–70. doi: 10.1016/j.autrev.2007.08.001.PubMedCrossRefGoogle Scholar
  24. 24.
    Salvi R, Peclat V, So A, Busso N. Enhanced expression of genes involved in coagulation and fibrinolysis in murine arthritis. Arthritis Res. 2000;2(6):504–12.PubMedCrossRefGoogle Scholar
  25. 25.
    Verdrengh M, Jonsson IM, Holmdahl R, Tarkowski A. Genistein as an anti-inflammatory agent. Inflamm Res. 2003;52(8):341–6. doi: 10.1007/s00011-003-1182-8.PubMedCrossRefGoogle Scholar
  26. 26.
    Esmon CT. Crosstalk between inflammation and thrombosis. Maturitas. 2004;47(4):305–14. doi: 10.1016/j.maturitas.2003.10.015.PubMedCrossRefGoogle Scholar
  27. 27.
    Sagripanti A, Morganti M, Carpi A, Cupisti A, Nicolini A, Barsotti M, et al. Uremic medium increases cytokine-induced PAI-1 secretion by cultured endothelial cells. Biomed Pharmacother. 1998;52(7–8):298–302.PubMedCrossRefGoogle Scholar
  28. 28.
    van Hinsbergh VW, van den Berg EA, Fiers W, Dooijewaard G. Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells. Blood. 1990;75(10):1991–8.PubMedGoogle Scholar
  29. 29.
    Ingegnoli F, Fantini F, Favalli EG, Soldi A, Griffini S, Galbiati V, et al. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. J Autoimmun. 2008;31(2):175–9. doi: 10.1016/j.jaut.2008.07.002.PubMedCrossRefGoogle Scholar
  30. 30.
    Jin T, Bokarewa M, Amu S, Tarkowski A. Impact of short-term therapies with biologics on prothrombotic biomarkers in rheumatoid arthritis. Clin Exp Rheumatol. 2009;27(3):491–4. doi: 2631[pii].PubMedGoogle Scholar
  31. 31.
    Varisco PA, Peclat V, van Ness K, Bischof-Delaloye A, So A, Busso N. Effect of thrombin inhibition on synovial inflammation in antigen induced arthritis. Ann Rheum Dis. 2000;59(10):781–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Li J, Guo Y, Holmdahl R, Ny T. Contrasting roles of plasminogen deficiency in different rheumatoid arthritis models. Arthritis Rheum. 2005;52(8):2541–8. doi: 10.1002/art.21229.PubMedCrossRefGoogle Scholar
  33. 33.
    Van Ness K, Chobaz-Peclat V, Castellucci M, So A, Busso N. Plasminogen activator inhibitor type-1 deficiency attenuates murine antigen-induced arthritis. Rheumatology (Oxford). 2002;41(2):136–41.CrossRefGoogle Scholar
  34. 34.
    Yang YH, Carmeliet P, Hamilton JA. Tissue-type plasminogen activator deficiency exacerbates arthritis. J Immunol. 2001;167(2):1047–52.PubMedGoogle Scholar
  35. 35.
    Guo Y, Li J, Hagstrom E, Ny T. Protective effects of plasmin(ogen) in a mouse model of Staphylococcus aureus-induced arthritis. Arthritis Rheum. 2008;58(3):764–72. doi: 10.1002/art.23263.PubMedCrossRefGoogle Scholar
  36. 36.
    Marty I, Peclat V, Kirdaite G, Salvi R, So A, Busso N. Amelioration of collagen-induced arthritis by thrombin inhibition. J Clin Invest. 2001;107(5):631–40. doi: 10.1172/JCI11064.PubMedCrossRefGoogle Scholar
  37. 37.
    Cook AD, Braine EL, Campbell IK, Hamilton JA. Differing roles for urokinase and tissue-type plasminogen activator in collagen-induced arthritis. Am J Pathol. 2002;160(3):917–26.PubMedCrossRefGoogle Scholar
  38. 38.
    Cook AD, De Nardo CM, Braine EL, Turner AL, Vlahos R, Way KJ, et al. Urokinase-type plasminogen activator and arthritis progression: role in systemic disease with immune complex involvement. Arthritis Res Ther. 2010;12(2):R37. doi: 10.1186/ar2946.PubMedCrossRefGoogle Scholar
  39. 39.
    Li J, Ny A, Leonardsson G, Nandakumar KS, Holmdahl R, Ny T. The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis. Am J Pathol. 2005;166(3):783–92. doi: 166/3/783[pii].PubMedCrossRefGoogle Scholar
  40. 40.
    Calabozo M, Aretxabala I, Alonso-Ruiz A, Perez-Ruiz F, Fraiz E, Ruiz-Lucea E, et al. Intraarticular urokinase: a new drainage technique for synovial effusions with rice bodies. J Rheumatol. 1998;25(2):394–5.PubMedGoogle Scholar
  41. 41.
    Sturrock RD, Watkin C, Williamson T, Dick WC. Intra-articular urokinase in rheumatoid arthritis. Ann Rheum Dis. 1974;33(2):124–5.PubMedCrossRefGoogle Scholar
  42. 42.
    Imiela J, Nosarzewski J, Górski A. Oral heparin in the treatment of rheumatoid arthritis. Arch Immunol Ther Exp (Warsz). 1995;43(5–6):313–5.Google Scholar

Copyright information

© Springer Basel AG 2011

Authors and Affiliations

  • Jakub Kwieciński
    • 1
    Email author
  • Elisabet Josefsson
    • 1
  • Tao Jin
    • 1
  1. 1.Department of Rheumatology and Inflammation Research, Institute of Medicine at Sahlgrenska AcademyUniversity of GothenburgGothenburgSweden

Personalised recommendations